Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
Considering the pathogenesis of several allergic skin diseases to be investigated in this
study as well as the pharmacodynamic mechanisms of the association of dexamethasone and
clemastine fumarate, it is believed that the components of topical medication may act
synergistically in the reduction of signs and symptoms of the diseases in question. Therefore
it is expected that the association promotes results significantly superior to dexamethasone
Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
The aim of this study is to prove the efficacy of the dexamethasone 0.5 mg + 1 mg clemastine
fumarate tablet compared to 0.5 mg of dexamethasone in reducing the signs and symptoms of
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and
impaired quality of life due specially pruritus and physical visible skin lesions. The
propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g +
dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
University of California, San Francisco
The main purpose of this study is to assess clemastine as a remyelinating agent in patients
with relapsing forms of multiple sclerosis. The study will also evaluate the tolerability of
clemastine, originally approved as first-generation antihistamine, in patients with multiple
sclerosis. Study procedures will include assessments for evidence of remyelination in the
anterior visual pathway and in the brain using electrophysiologic techniques and magnetic
resonance imaging. The study will also assess the robustness and stability of this clinical
effect in patients taking clemastine for up to 3 months. Patients in this study can remain on
their standard disease modifying treatment during the course of the study. However, patients
cannot participate in any other investigational new drug research study concurrently.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.